Algernon Pharmaceuticals Announces Last Patient Out in Multinational Phase 2b/3 Human Study of Ifenprodil for COVID-19

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the " Company " or " Algernon ") a clinical stage pharmaceutical development company, is pleased to announce that the last patient from the Phase 2b part of its multinational Phase 2b3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19, has now completed treatment as well as the required two-week follow up.

The Company announced positive trending interim data for the Phase 2b part of it Phase 2b/3 Ifenprodil COVID-19 Study, on December 15, 2020. The Company is projecting the final data set will be available before the end of February, 2020.

"This is another important step for the Company," said Christopher J. Moreau, CEO of Algernon Pharmaceuticals. "Now that we have announced final patient out of the Ifenprodil COVID-19 study, we can begin preparations for the final data report."

The Company advises that it is not making any express or implied claims that Ifenprodil has the ability to eliminate, cure or contain COVID-19 (or the SARS-2 Coronavirus) at this time.

About NP-120 (Ifenprodil)

NP-120 (Ifenprodil) is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (Glu2NB). Ifenprodil prevents glutamate signalling. The NMDA receptor is found on many tissues including lung cells, T-cells, and neutrophils.

The Company believes Ifenprodil can reduce the infiltration of neutrophils and T-cells into the lungs where they can release glutamate and cytokines respectively. The latter can result in the highly problematic cytokine storm that contributes to the loss of lung function and ultimately death as has been reported in COVID-19 infected patients.

About Algernon Pharmaceuticals Inc.

Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.

Algernon has filed new intellectual property rights globally for NP-120 (Ifenprodil) for the treatment of respiratory diseases and is working to develop a proprietary injectable and slow release formulation.

CONTACT INFORMATION

Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701
info@algernonpharmaceuticals.com  
  investors@algernonpharmaceuticals   .com
  www.algernonpharmaceuticals.com

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

The Conversation (0)
Biotech therapy capsule containing DNA strand surrounded by cells.

Top 4 Canadian Biotech Stocks (Updated January 2025)

Biotech is a dynamic industry that is driving scientific advancements and innovation in healthcare. In Canada, the biotech industry is home to companies pursuing cutting-edge therapies and medical technologies.

According to Grandview Research, the global biotech market is expected to grow at a compound annual growth rate of 13.96 percent between 2024 and 2030 to reach a value of US$3.08 trillion.

Here, the Investing News Network profiles the five best-performing Canadian biotech stocks based on their year-on-year gains.

Keep reading...Show less
Cizzle Brands Launching Spoken Nutrition as its Latest Performance-Driven Brand for Athletes

Cizzle Brands Launching Spoken Nutrition as its Latest Performance-Driven Brand for Athletes

Spoken Nutrition™ is a premium brand of athlete-grade nutraceuticals that carry the prestigious NSF Certified for Sport® qualification, making Spoken products eligible for use by athletes in several major-league and minor-league organizations, as well as the NCAA. With purchase orders secured from many professional sports teams, including multiple MLB teams for use during Spring Training leading into the 2025 regular baseball season, the launch of Spoken Nutrition™ cements Cizzle Brands Corporation as a global leader in sports nutrition.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Cizzle Brands Launching Spoken Nutrition as its Latest Performance-Driven Brand for Athletes

Cizzle Brands Launching Spoken Nutrition as its Latest Performance-Driven Brand for Athletes

Spoken Nutrition™ is a premium brand of athlete-grade nutraceuticals that carry the prestigious NSF Certified for Sport® qualification, making Spoken products eligible for use by athletes in several major-league and minor-league organizations, as well as the NCAA. With purchase orders secured from many professional sports teams, including multiple MLB teams for use during Spring Training leading into the 2025 regular baseball season, the launch of Spoken Nutrition™ cements Cizzle Brands Corporation as a global leader in sports nutrition.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×